- Front Page
- SIEF for Cetrimonium Bromide (CTAB)
- SIEF for tetradonium bromide
- SIEF for tetradonium bromide
- Why us
- Download & Publications
- Contact us
Annual Biologics Manufacturing Korea -Visit us at booth # 11 and find out more about how recombinant insulin have a positive effect on your cell lines
Since 2012, Biologics Manufacturing Korea has witnessed huge success in bringing over 550 biologics industry pioneers from both Korea and overseas. With the mission to facilitate development and manufacturing of high-quality biologic drugs and vaccines in Korea for the world market, Biologics Manufacturing Korea is going to continue its legacy.
Brenntag Specialties Inc. (BSI) Expands Pharmaceutical, OTC and Personal Care Product Offering With Novo Nordisk Pharmatech Pharmaceutical Grade Quaternary Ammonium Compounds.
Novo Nordisk Pharmatech and Brenntag Specialties, Inc. (BSI) have entered into a distribution agreement for Pharmaceutical Grade Quaternary Ammonium Compounds into the Pharmaceutical and OTC Markets in the United States & Puerto Rico.
“Our partnership with Novo Nordisk Pharmatech demonstrates our commitment to providing innovative solutions and differentiated value to our customers by strategically expanding our principal relationships and product lines.” said Steve Brauer, President of Brenntag Specialties, Inc. “The product line offering from Novo Nordisk Pharmatech furthers our reach into the pharmaceutical, OTC, and personal care markets”
Novo Nordisk Pharmatech manufactures its Pharmaceutical Grade Quaternary Ammonium Compounds in accordance with the highest cGMP standards in the market- the ICH Q7A Guide for Active Pharmaceutical Ingredients.
The new product offering includes:
– Benzalkonium Chloride and Cetrimide solutions
– Benzalkonium Chloride 95%
– Crystalline Cetrimide and Cetyl Trimethyl Ammonium Bromide
An innovative synthesis process makes Novo Nordisk Pharmatech a leading supplier of crystalline quaternary ammonium compounds. They have excellent antimicrobial and surface-active properties rendering them suitable for a variety of applications. High levels of purity make them particularly suited for specialized pharmaceutical applications, such as polysaccharide vaccine production and precipitation of DNA (gene therapy) vaccines. Quaternary ammonium compounds act either as preservatives or active ingredients in many ophthalmic, nasal, oral and topical drugs and in a variety of surgical scrubs, medicated solutions, ointments and creams.
Novo Nordisk Pharmatech manufactures quaternary ammonium compounds using only high-purity tertiary amines with various alkyl chain lengths, normally ranging from C12 to C18. The properties of our quaternary ammonium compounds can vary according to the alkyl chain length, but they all offer common attributes including:
- Proven record of efficacy against a broad spectrum of microorganisms
- Effective through a wide pH range
- Odourless and colourless in product formulation
- Surface active / adhesive cationic agent
- Very stable, proven under ICH Q1 Stability Protocols
- Five-year shelf life
- Drug Master Files available for reference
Brenntag, the global market leader in chemical distribution, covers all major markets with its extensive product and service portfolio. Headquartered in Mülheim an der Ruhr, Germany, the company operates a global network with more than 490 locations in 72 countries. In 2014, the company, which has a global workforce of more than 13,500, generated sales of EUR 10.0 billion (USD 13.3 billion). Brenntag connects chemical manufacturers and chemical users. The company supports its customers and suppliers with tailor-made distribution solutions for industrial and specialty chemicals. With over 10,000 products and a world-class supplier base, Brenntag offers one-stop-shop solutions to around 170,000 customers. This includes specific application technology, an extensive technical support and value-added services such as just-in-time delivery, product mixing, formulation, repackaging, inventory management and drum return handling. Long-standing experience and local excellence in the individual countries characterize the global market leader for chemical distribution.
Novo Nordisk Pharmatech enters important distribution agreement with Azelis for pharmaceutical grade quaternary ammonium compounds
Novo Nordisk Pharmatech A/S has entered into an agreement with Azelis for the distribution of pharmaceutical grade quaternary ammonium compounds (quats) to the pharmaceutical and medical device markets in Germany, Spain, Portugal, UK and Ireland.
Matthew Dickman, Market Segment Director Pharma Azelis explains: “Novo Nordisk Pharmatech is the industry leader in pharmaceutical grade quats and we are delighted they have chosen Azelis Pharma as their distribution partner for the development of these markets. Novo Nordisk Pharmatech’s quats complement an existing Azelis portfolio of pharma antimicrobials. Alongside established uses of quats, our Pharma experts see potential new applications in the growing wound care market. Our local teams, who work with customers to support both their current and NPD requirements, will be investigating these options in the coming period.”
Novo Nordisk Pharmatech manufactures its quats (Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide, including customised grades) to the highest (c)GMP standards. Their site (Koege/Denmark) is audited by the Danish Medicines Agency and US-FDA. Products comply with the latest major pharmacopoeia and are supported by CEPs, DMFs and a comprehensive package of regulatory and quality assurance documents.
“We are very happy to work with Azelis as our distribution partner for our cGMP Quats. Novo Nordisk Pharmatech’s FeF™Quats products fit perfectly with Azelis existing antimicrobial portfolio enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma teams of Azelis are experts in working with customers to support their current and product development requirements.” says Steve Profit, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.
Azelis is the leading global speciality chemicals distributor providing a diverse range of innovative products and services. Dedicated teams serve customers in the following industries: Personal Care, Pharma, Food & Health, Animal Nutrition, Specialty Agri/Horti, Homecare & Industrial Cleaning, CASE (coatings, adhesives, sealants, elastomers) Chemicals, Lubricants & Metal Working Fluids and Rubber & Plastic Additives. Through sourcing and distribution channels in every major market around the world, Azelis with its corporate service centre in Antwerp, Belgium, offers chemical producers market penetration, in-depth local knowledge, value-added services and tailored multi-territory solutions. Azelis has a turnover of ca. €1.5 billion and employs around 1,500 knowledgeable people located in more than 45 facilities in over 35 countries across the EMEA, Asia Pacific and Americas regions.
For more information, please visit: Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S Annual Report 2016
Our Annual Report reviews the performance of Novo Nordisk Pharmatech A/S in 2016.
Download the full performance summary
Novo Nordisk Pharmatech A/S (abbreviated as NNPR) is a fully owned subsidary of Novo Nordisk A/S. Novo Nrodisk is the biggest customer buying Silica gel, Enzymes, Analytical Columns and Micro-analysis services.
NNPR are manufacturing and selling active pharmaceutical ingredients (API) and excipients to the pharmaceutical and biopharmaceutical industry comprising of quaternary amines and Human Insulin. The majority of these products are exported throughout the world, with the US as the largest market.
Development in 2016
NNPR’s revenue in 2016 was DKK 669,077k which was 32 % higher than in 2015. The underlying resaons for the increase were:
- Strong sales development on exported products with a growth of 19 % derived from a combination of increased volume price and exchange rate.
- Increase in sales to Novo Nordisk of 51 % compared to 2015. 2015 included a one-off reduction in IPC costs due to the new valuation method of valuing inventory.
Knowledge capital of NNPR
It is the foundation of NNPR to be a quality supplier of high value products to the pharmaceutical and the biopharmaceutical industry. The knowledge capital of NNPR is within 6 main areas: silica gel technology, purification of proteins, micro-analysis, analytical columns, cGMP production of quaternary amines and insulin for technical use.
NNPR is a competence centre for the use of silica gels for chromatographical purification in Novo Nordisk. The technological knowledge is secured by interaction with users in production, process support and R&D departments in Novo Nordisk. Furthermore improvements are implemented to the mechanical and chemical lifetime of the product, often in close cooperation with the suppliers.
This work forms the basis for continuous improvements of the products in NNPR and contributes to reducing costs in Novo Nordisk for purification of products and this is expected to continue.
NNPR is building up knowledge within the application of insulin as excipients in the production of biopharmaceutical products. This will support and develop that part of NNPR’s business.
Corporate Social Responsibility
NNPR strives to conduct its activities in a financially, environmentally and socially responsible way.
The Corporate social responsibility equals the concept of the Triple Bottom Line. The environmental and social activities are described below under “Health, safety and environment”.
For NNPR, climate change is part of our approach to environmental management and encompasses ongoing focus on saving energy and reduction of emissions of organic solvents to the atmosphere.
With respect to human rights, NNPR defines the company’s focus as its own employees and their rights and well-being. Therefore, beside ensuring legal compliance with worker’s rights, discrimination and the right to organize at all times, our activities towards human rights include general safety and prevention of accidents, prevention of stress and work related illnesses as wells as ensuring general good health
among our employees.
NNPR supports the fight against bribery in international business, as bribery undermines sustainable development and the rule of law. We are committed to complying with all local law and regulations, including the United States’ Foreign Corrupt Practices Act and the United Kingdom’s Bribery Act.
Selectchemie AG Expands Pharmaceutical, OTC and Personal Care Product Offering With
Novo Nordisk Pharmatech A/S Pharmaceutical Grade Quaternary Ammonium Compounds for Switzerland, Austria and Eastern Europe markets.
We are proud to announce that we were inspected by the FDA in June 2016.
The inspection had the best possible outcome with no observations.
We are very pleased to add this proof of quality and commitment to the pharmaceutical industry to our track record certifications.
This addition will also support our strengthened presence in the US through our new distribution partner, Brenntag Specialties.
Novo Nordisk Pharmatech A/S receives a CPHI Award
Novo Nordisk Pharmatech A/S has received the CPHI Award 2015 for most sustainable stand together with Novozymes. We are proud to have received this award in recognition of the fact that the stand was judged 1st place out of 2.500 exhibitors at this global event. The evaluation criteria was: risk assessment, stand construction, low material waste, reusable stand material, environmental impact and CSR (corporate social responsibility)
Read the article in BioProcess International
Read the interview with our Managing Director, Rasmus Hother le Fevre in the BioProcess International publication:
MD Logistics continues to catch the eye of leading industry publications, earning two notable awards for its continued growth in 2015.
Global Trade has named MD Logistics a Top 3PL, while Inbound Logistics honored MD Logistics as a Top 100 Third-Party Logistics Provider for 2015 for a fourth consecutive year.
The awards come as MD Logistics continues to grow with customers, expanding cooler capacities in its West and Midwest facilities the past two years, as well as implementing extreme cold chain solutions for biopharmaceuticals.
The awards were bestowed after a lengthy deliberation process, which included personal interviews and thorough research. In the end, MD Logistics’ continued ability to adapt to customers needs stood apart from the competition.
read more here: